Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add more filters










Database
Language
Publication year range
1.
BMC Genomics ; 23(1): 688, 2022 Oct 05.
Article in English | MEDLINE | ID: mdl-36199042

ABSTRACT

BACKGROUND: MicroRNAs (miRNAs) are important post-transcriptional regulators involved in the control of a range of processes, including symbiotic interactions in plants. MiRNA involvement in arbuscular mycorrhizae (AM) symbiosis has been mainly studied in model species, and our study is the first to analyze global miRNA expression in the roots of AM colonized switchgrass (Panicum virgatum), an emerging biofuel feedstock. AM symbiosis helps plants gain mineral nutrition from the soil and may enhance switchgrass biomass production on marginal lands. Our goals were to identify miRNAs and their corresponding target genes that are controlling AM symbiosis in switchgrass. RESULTS: Through genome-wide analysis of next-generation miRNA sequencing reads generated from switchgrass roots, we identified 122 mature miRNAs, including 28 novel miRNAs. By comparing miRNA expression profiles of AM-inoculated and control switchgrass roots, we identified 15 AM-responsive miRNAs across lowland accession "Alamo", upland accession "Dacotah", and two upland/lowland F1 hybrids. We used degradome sequencing to identify target genes of the AM-responsive miRNAs revealing targets of miRNAs residing on both K and N subgenomes. Notably, genes involved in copper ion binding were targeted by downregulated miRNAs, while upregulated miRNAs mainly targeted GRAS family transcription factors. CONCLUSION: Through miRNA analysis and degradome sequencing, we revealed that both upland and lowland switchgrass genotypes as well as upland-lowland hybrids respond to AM by altering miRNA expression. We demonstrated complex GRAS transcription factor regulation by the miR171 family, with some miR171 family members being AM responsive while others remained static. Copper miRNA downregulation was common amongst the genotypes tested and we identified superoxide dismutases and laccases as targets, suggesting that these Cu-miRNAs are likely involved in ROS detoxification and lignin deposition, respectively. Other prominent targets of the Cu miRNAs were blue copper proteins. Overall, the potential effect of AM colonization on lignin deposition pathways in this biofuel crop highlights the importance of considering AM and miRNA in future biofuel crop development strategies.


Subject(s)
MicroRNAs , Mycorrhizae , Panicum , Biofuels , Copper , Lignin , MicroRNAs/genetics , MicroRNAs/metabolism , Mycorrhizae/metabolism , Panicum/metabolism , Reactive Oxygen Species , Soil , Superoxides , Transcription Factors
2.
PLoS One ; 10(7): e0132063, 2015.
Article in English | MEDLINE | ID: mdl-26135305

ABSTRACT

Preeclampsia is characterized by reduced placental perfusion with placental ischemia and hypertension during pregnancy. Preeclamptic women also exhibit a heightened inflammatory state and greater number of neutrophils in the vasculature compared to normal pregnancy. Since neutrophils are associated with tissue injury and inflammation, we hypothesized that neutrophils are critical to placental ischemia-induced hypertension and fetal demise. Using the reduced uteroplacental perfusion pressure (RUPP) model of placental ischemia-induced hypertension in the rat, we determined the effect of neutrophil depletion on blood pressure and fetal resorptions. Neutrophils were depleted with repeated injections of polyclonal rabbit anti-rat polymorphonuclear leukocyte (PMN) antibody (antiPMN). Rats received either antiPMN or normal rabbit serum (Control) on 13.5, 15.5, 17.5, and 18.5 days post conception (dpc). On 14.5 dpc, rats underwent either Sham surgery or clip placement on ovarian arteries and abdominal aorta to reduce uterine perfusion pressure (RUPP). On 18.5 dpc, carotid arterial catheters were placed and mean arterial pressure (MAP) was measured on 19.5 dpc. Neutrophil-depleted rats had reduced circulating neutrophils from 14.5 to 19.5 dpc compared to Control, as well as decreased neutrophils in lung and placenta on 19.5 dpc. MAP increased in RUPP Control vs Sham Control rats, and neutrophil depletion attenuated this increase in MAP in RUPP rats without any effect on Sham rats. The RUPP-induced increase in fetal resorptions and complement activation product C3a were not affected by neutrophil depletion. Thus, these data are the first to indicate that neutrophils play an important role in RUPP hypertension and that cells of the innate immune system may significantly contribute to pregnancy-induced hypertension.


Subject(s)
Hypertension, Pregnancy-Induced/prevention & control , Ischemia/physiopathology , Leukocyte Reduction Procedures , Neutrophils/physiology , Placenta/blood supply , Animals , Complement C3a/analysis , Disease Models, Animal , Female , Hypertension, Pregnancy-Induced/blood , Hypertension, Pregnancy-Induced/etiology , Hypertension, Pregnancy-Induced/immunology , Hypertension, Pregnancy-Induced/physiopathology , Immune Sera , Immunity, Innate , Ischemia/complications , Ischemia/immunology , Leukocyte Count , Neutrophils/immunology , Oxidative Stress , Placental Circulation , Pre-Eclampsia/etiology , Pre-Eclampsia/immunology , Pre-Eclampsia/physiopathology , Pre-Eclampsia/prevention & control , Pregnancy , Rats , Rats, Sprague-Dawley , Vascular Endothelial Growth Factor A/blood
3.
J Pharmacol Exp Ther ; 351(2): 344-51, 2014 Nov.
Article in English | MEDLINE | ID: mdl-25150279

ABSTRACT

Early-onset pre-eclampsia is characterized by decreased placental perfusion, new-onset hypertension, angiogenic imbalance, and endothelial dysfunction associated with excessive activation of the innate immune complement system. Although our previous studies demonstrated that inhibition of complement activation attenuates placental ischemia-induced hypertension using the rat reduced uterine perfusion pressure (RUPP) model, the important product(s) of complement activation has yet to be identified. We hypothesized that antagonism of receptors for complement activation products C3a and C5a would improve vascular function and attenuate RUPP hypertension. On gestational day (GD) 14, rats underwent sham surgery or vascular clip placement on ovarian arteries and abdominal aorta (RUPP). Rats were treated once daily with the C5a receptor antagonist (C5aRA), PMX51 (acetyl-F-[Orn-P-(D-Cha)-WR]), the C3a receptor antagonist (C3aRA), SB290157 (N(2)-[(2,2-diphenylethoxy)acetyl]-l-arginine), or vehicle from GD 14-18. Both the C3aRA and C5aRA attenuated placental ischemia-induced hypertension without affecting the decreased fetal weight or decreased concentration of free circulating vascular endothelial growth factor (VEGF) also present in this model. The C5aRA, but not the C3aRA, attenuated placental ischemia-induced increase in heart rate and impaired endothelial-dependent relaxation. The C3aRA abrogated the acute pressor response to C3a peptide injection, but it also unexpectedly attenuated the placental ischemia-induced increase in C3a, suggesting nonreceptor-mediated effects. Overall, these results indicate that both C3a and C5a are important products of complement activation that mediate the hypertension regardless of the reduction in free plasma VEGF. The mechanism by which C3a contributes to placental ischemia-induced hypertension appears to be distinct from that of C5a, and management of pregnancy-induced hypertension is likely to require a broad anti-inflammatory approach.


Subject(s)
Cardiovascular System/immunology , Cardiovascular System/physiopathology , Complement Activation/immunology , Complement C3a/immunology , Complement C5a/immunology , Hypertension/immunology , Hypertension/physiopathology , Animals , Complement C3a/antagonists & inhibitors , Complement C5a/antagonists & inhibitors , Disease Models, Animal , Endothelium, Vascular/immunology , Endothelium, Vascular/physiopathology , Female , Heart Rate/immunology , Ischemia/immunology , Ischemia/physiopathology , Placenta/immunology , Pregnancy , Rats , Receptors, Complement/immunology , Vascular Endothelial Growth Factor A/immunology
4.
Pediatr Allergy Immunol ; 25(2): 180-6, 2014 Mar.
Article in English | MEDLINE | ID: mdl-24520985

ABSTRACT

BACKGROUND: Infants born prematurely are often treated with supplemental oxygen, which can increase their risk for airway hyper-responsiveness (AHR), asthma, reduced lung function, and altered responses to respiratory viral infections later in childhood. Likewise, exposure of newborn mice to hyperoxia alters baseline pulmonary mechanics and the host response to influenza A virus infection in adult mice. Here, we use this mouse model to test the hypothesis that neonatal hyperoxia also promotes AHR and exacerbated allergen-induced symptoms in adult mice. METHODS: Baseline lung mechanics and AHR measured by methacholine provocation were assessed in adult male and female mice exposed to room air or 100% oxygen (hyperoxia) between post-natal days 0-4. AHR and lung inflammation were evaluated after adult female mice were sensitized with ovalbumin (OVA) plus alum and challenged with aerosolized OVA. RESULTS: Baseline lung compliance increased and resistance decreased in adult female, but not male, mice exposed to neonatal hyperoxia compared with siblings exposed to room air. Neonatal hyperoxia significantly enhanced methacholine-induced AHR in female mice, but did not affect allergen-induced AHR to methacholine or lung inflammation. CONCLUSION: Increased incidence of AHR and asthma is reported in children born prematurely and exposed to supplemental oxygen. Our findings in adult female mice exposed to hyperoxia as neonates suggest that this AHR reported in children born prematurely may reflect non-atopic wheezing due to intrinsic structural changes in airway development.


Subject(s)
Bronchial Hyperreactivity/physiopathology , Bronchoconstriction , Hyperoxia/physiopathology , Lung/physiopathology , Pneumonia/physiopathology , Age Factors , Airway Resistance , Animals , Animals, Newborn , Bronchial Hyperreactivity/chemically induced , Bronchial Hyperreactivity/diagnosis , Bronchial Provocation Tests , Bronchoconstrictor Agents/pharmacology , Disease Models, Animal , Female , Hyperoxia/complications , Hyperoxia/diagnosis , Lung Compliance , Male , Methacholine Chloride , Mice, Inbred C57BL , Molecular Sequence Data , Ovalbumin , Pneumonia/chemically induced , Pneumonia/diagnosis , Risk Factors , Sex Factors
5.
Mol Immunol ; 56(1-2): 91-7, 2013 Nov.
Article in English | MEDLINE | ID: mdl-23685261

ABSTRACT

Preeclampsia is a major obstetric problem defined by new-onset hypertension and proteinuria associated with compromised placental perfusion. Although activation of the complement system is increased in preeclampsia compared to normal pregnancy, it remains unclear whether excess complement activation is a cause or consequence of placental ischemia. Therefore, we hypothesized that complement activation is critical for placental ischemia-induced hypertension. We employed the reduced utero-placental perfusion pressure (RUPP) model of placental ischemia in the rat to induce hypertension in the third trimester and evaluated the effect of inhibiting complement activation with a soluble recombinant form of an endogenous complement regulator, human complement receptor 1 (sCR1; CDX-1135). On day 14 of a 21-day gestation, rats received either RUPP or Sham surgery and 15 mg/kg/day sCR1 or saline intravenously on days 14-18. Circulating complement component 3 decreased and complement activation product C3a increased in RUPP vs. Sham (p<0.05), indicating complement activation had occurred. Mean arterial pressure (MAP) measured on day 19 increased in RUPP vs. Sham rats (109.8±2.8 mmHg vs. 93.6±1.6 mmHg). Treatment with sCR1 significantly reduced elevated MAP in RUPP rats (98.4±3.6 mmHg, p<0.05) and reduced C3a production. Vascular endothelial growth factor (VEGF) decreased in RUPP compared to Sham rats, and the decrease in VEGF was not affected by sCR1 treatment. Thus, these studies have identified a mechanistic link between complement activation and the pregnancy complication of hypertension apart from free plasma VEGF and have identified complement inhibition as a potential treatment strategy for placental ischemia-induced hypertension in preeclampsia.


Subject(s)
Complement Activation/physiology , Hypertension/physiopathology , Ischemia/physiopathology , Placenta/physiopathology , Animals , Arterial Pressure/drug effects , Carotid Arteries/drug effects , Carotid Arteries/physiopathology , Complement Activation/drug effects , Complement C3/metabolism , Dose-Response Relationship, Drug , Female , Humans , Hypertension/blood , Hypertension/metabolism , In Vitro Techniques , Male , Nitroprusside/pharmacology , Placenta/blood supply , Placenta/metabolism , Pre-Eclampsia/blood , Pre-Eclampsia/metabolism , Pre-Eclampsia/physiopathology , Pregnancy , Rats , Rats, Sprague-Dawley , Receptors, Complement/administration & dosage , Time Factors , Uterus/blood supply , Uterus/metabolism , Uterus/physiopathology , Vascular Endothelial Growth Factor A/blood , Vascular Endothelial Growth Factor A/metabolism , Vascular Endothelial Growth Factor Receptor-1/blood , Vascular Endothelial Growth Factor Receptor-1/metabolism , Vasodilation/drug effects , Vasodilator Agents/pharmacology
6.
Am J Cardiol ; 105(9): 1317-26, 2010 May 01.
Article in English | MEDLINE | ID: mdl-20403486

ABSTRACT

The effects of radiofrequency catheter ablation (RFCA) on left atrial (LA) size, volumes, and function in patients with atrial fibrillation (AF) are not well understood. The aim of this study was to systematically review the effects of RFCA on LA size, volumes, and function in patients with AF. Medline, the Web of Science, the Cochrane Central Register of Controlled Trials, and the reference lists of retrieved reports were searched for relevant studies through April 2009. Studies conducted in patients with AF were included if their primary outcomes were changes in LA size or volumes and/or function before and after RFCA. Weighted mean differences for changes in LA diameter, LA maximum volume, LA minimum volume, LA ejection fraction, and LA active emptying fraction were estimated using fixed- and random-effects meta-analyses. Seventeen relevant studies (enrolling 869 patients) among 192 identified studies were included in the final analysis. Compared to preablation values, there were significant decreases in LA diameter and LA volumes at postablation follow-up. However, compared to preablation values, there were no significant differences in LA ejection fraction and LA active emptying fraction at postablation follow-up. Decreases in LA diameter and LA volumes remained significant in those without AF recurrence but not in those with AF recurrence. LA ejection fraction and LA active emptying fraction did not decrease in patients without AF recurrence, whereas they decreased in patients with AF recurrence. In conclusion, successful RFCA in patients with AF significantly decreases LA size and volumes and does not seem to adversely affect LA function.


Subject(s)
Atrial Fibrillation , Atrial Function/physiology , Cardiac Volume/physiology , Catheter Ablation , Heart Atria/physiopathology , Atrial Fibrillation/diagnostic imaging , Atrial Fibrillation/physiopathology , Atrial Fibrillation/surgery , Humans , Postoperative Period , Ultrasonography
SELECTION OF CITATIONS
SEARCH DETAIL
...